ArticleCureus2025
A Sudden Expansion: Acute Subdural Hematoma From Extramedullary Acute Myeloid Leukemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chloromas are extramedullary agglomerations of malignant myeloid blast cells, also known as myeloid sarcoma. Myeloid sarcoma of the central nervous system (CNS) is a very rare presentation of extramedullary leukemic mass infiltration. This may be seen as an intracranial mass due to invasion of the brain parenchyma or as leukemic infiltration of the meninges. Such infiltration may present as a subdural hematoma (SDH), particularly in coagulopathic or immunocompromised patients undergoing chemotherapy. We present a 63-year-old male with acute myeloid leukemia (AML), previously treated with azacitidine/venetoclax induction and intrathecal methotrexate, who was admitted with abdominal thromboses and started on therapeutic anticoagulation. The patient later developed acute encephalopathy, and imaging demonstrated a large left-sided acute-on-subacute SDH with mass effect. Despite anticoagulation reversal and surgical intervention, the patient experienced recurrent hemorrhage. Histopathology of the subdural membrane tissue confirmed AML with monocytic differentiation. The clinical course was further complicated by tumor lysis syndrome, metabolic acidosis, and acute liver failure. The patient expired following withdrawal of life-sustaining treatment. This case highlights a rare, catastrophic CNS manifestation of AML in the form of a dural-based chloroma inducing a subacute-chronic SDH. Dural metastasis should be considered in patients with hematologic malignancies and subacute SDH. Although SDHs can typically be treated with good outcomes following surgical evacuation, those due to leukemic infiltration from AML - especially high-risk phenotypes - may portend less favorable outcomes, due to concomitant coagulopathy and being a marker for more aggressive hematologic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.